Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol in Diabetic Patients With Coronary Artery Disease
NCT03385135Unknown
- Sponsor
- University of Tunis El Manar
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of allopurinol in coronary artery disease (CAD), sponsored by University of Tunis El Manar. Primary endpoint: Endothelium-dependent vasodilation at 2 months. Status: unknown.
02
Drugs
allopurinol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03385135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385135.